Who Still Synthesizes in Los Angeles?
AMVAC's Los Angeles plant keeps its address, its payroll and its drums, and loses the ability to make a molecule from scratch on December 31. The whole public record of it is a transformation-expense footnote, no WARN notice appears in either California register, and last quarter the reorganization spent $682,000.
If you buy an active ingredient produced at 4100 East Washington Boulevard, you have until December.
That address is AMVAC's Los Angeles plant. It is not on any closure list, it has not filed a WARN notice, and no trade publication we could find this week has written a word about it.
The plant will still be there in January, still making product, still shipping drums.
What it will not be doing is synthesis.
"What does a supplier owe you when a site keeps its address and loses its chemistry?"
What March Actually Said
American Vanguard filed its 2025 annual report on March 16 and buried the event in Note 17, under subsequent events. Management approved a plan on March 13 to "substantially reduce the production activities" at Los Angeles and move them to Axis, Alabama or Marsing, Idaho.
The company budgeted $8m to $10m of one-time pre-tax charges: roughly $4m of non-cash asset impairments, $2m of waste disposal, and $2m to $4m of everything else.
And it gave itself a deadline. The transfer was "expected to be completed by the second quarter of 2026."
Seven weeks later, in the first-quarter 10-Q, that date became December 31, 2026. It has held there through two filings since, including the one that landed Monday.
Two things changed in that same sentence, and they matter more than the date.
The rest of this brief is for subscribers.
The capacity math, the trade-flow read, and what it means for the products you buy.
$100 a month, or $800 a year.
Already a subscriber? Sign in